The reaction, called DRESS (drug reaction with eosinophilia and systemic symptoms) is rare but can be life-threatening. The FDA is now requiring makers of the drugs — Keppra, Keppra extended release, Elepsia extended release, Spritam, Onfi and Sympazan — to include a risk statement to their products.
The agency found 32 serious cases of DRESS for levetiracetam and 10 for clobazam. Most were hospitalized, and two patients who took levetiracetam died.
Symptoms of DRESS can appear two to eight weeks after the medications are administered, the FDA said, so clinicians are recommended to advise patients on signs of early symptoms, including fever and swollen lymph nodes. Healthcare workers are also advised to consider Stevens-Johnson syndrome and toxic epidermal necrolysis as possible reactions to the medications.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
